ArticleScientific reports2025
Probe amplifications in the Xpert MTB/RIF Ultra assay for non-tuberculous mycobacteria identified from diabetes mellitus and chronic kidney disease patients in Ethiopia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The demand for resources for mycobacterial culture makes diagnosing non-tuberculous mycobacteria (NTM) difficult. This study assessed probe amplifications in the Xpert MTB/RIF Ultra (Xpert Ultra) and Xpert MTB/RIF assays for different NTM species identified from diabetes mellitus (DM) and chronic kidney disease (CKD) patients. Since the sources of NTM isolates were DM and CKD patients, the study was limited to those patients. We ran the Xpert Ultra and Xpert MTB/RIF assays on 87 NTM culture isolates identified from DM (41 isolates) and CKD (46 isolates) patients, as well as seven distinct NTM ATCC strains. We also assessed the frequency of NTM species in 97 Xpert Ultra negative clinical specimens, which had probe amplification. Moreover, we assessed the effect of mixed NTM and M. tuberculosis infection and the presence of other bacteria (five gram-positive and five gram-negative) on probe amplification. Data were analyzed using SPSS version 27. Descriptive statistics were used to characterize each study variable. The cycle threshold (CT) values were compared across categories using the Mann-Whitney U and Kruskal-Wallis tests. The GeneXpert assays produced negative results for all 87 NTM isolates. Of them, 88.5% and 78.2% had probe amplification in the Xpert Ultra assay and Xpert MTB/RIF assay, respectively. The most often amplified probe was rpoB2 (77, 88.5%), followed by rpoB4 (10, 11.5%) in the Xpert Ultra, and Probe C (64, 73.6%), followed by Probe A (7, 8.0%) in the Xpert MTB/RIF. The median CT values for rpoB1, rpoB4, and rpoB2 were 30.9, 30.55, and 28.3, respectively. Whereas, for Probe C and Probe A, it was 29.2 and 26.3, respectively. The amplified probes were similar for NTM species. The rpoB2 CT value differed significantly among the NTM species (X
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.